Monoamine oxidase inhibitors and L-dopa

Hunter, K R; Boakes, A J; Laurence, D R; Stern, G M
August 1970
British Medical Journal;8/15/1970, Vol. 3 Issue 5719, p388
Academic Journal
No abstract available.


Related Articles

  • monoamine oxidase inhibitor.  // Taber's Cyclopedic Medical Dictionary (2009);2009, Issue 21, p1485 

    An encyclopedia entry for "monoamine oxidase inhibitor," is presented.

  • MAOI. Peters, Michael // BMA A-Z Family Medical Encyclopedia;2004, p488 

    An encyclopedia entry for "MAOI" is presented. It is an abbreviation for monoamine oxidase inhibitor drugs.

  • Deuterium-substituted l-DOPA displays increased behavioral potency and dopamine output in an animal model of Parkinson's disease: comparison with the effects produced by l-DOPA and an MAO-B inhibitor. Malmlöf, Torun; Feltmann, Kristin; Konradsson-Geuken, Åsa; Schneider, Frank; Alken, Rudolf-Giesbert; Svensson, Torgny; Schilström, Björn // Journal of Neural Transmission;Feb2015, Vol. 122 Issue 2, p259 

    The most effective treatment of Parkinson's disease (PD) l-DOPA is associated with major side effects, in particular l-DOPA-induced dyskinesia, which motivates development of new treatment strategies. We have previously shown that chronic treatment with a substantially lower dose of...

  • Results of the early stage PD MED study: revelation or recapitulation? Worth, Paul // Practical Neurology (BMJ Publishing Group);Dec2015, Vol. 15 Issue 6, p408 

    The author focuses on the validity of the results of the PD MED trial in relation to the potential of drugs in treating Parkinson's disease, based on a study published in the 2014 edition of "The Lancet." Topics discussed include the study tested various drugs like L-dopa, dopamine agonists and...

  • Serotonin syndrome: a reported case. Avarello, T.P.; Cottone, S. // Neurological Sciences;Sep2002 Supplement 2, Vol. 23, pS55 

    We describe a patient treated with SSRI and Ldopa, who developed agitation, rigidity, hyperreflexia, restlessness, autonomic instability, fever and finally death. CSF examination, MRI of the brain, laboratory investigations, except for serum CK, glycemia and WBC, were normal. His condition was...

  • Initial monoamine oxidase-A inhibition by moclobemide does not predict the therapeutic response in patients with major depression: A double blind, randomized study. Radat, Françoise; Berlin, I.; Spreux-Varoquaux, Odile; Elatki, Skander; Ferreri, Maurice; Puech, Alain J. // Psychopharmacology;1996, Vol. 127 Issue 4, p370 

    It is generally accepted that the clinical efficacy of monoamine oxidase inhibitors (MAOI) is related to inhibition of this enzyme. In order to evaluate the predictive ability of monoamine oxidase-A inhibition for therapeutic efficacy, the start of treatment effects of moclobemide, a selective,...

  • monoamine oxidase inhibitors. Peters, Michael // BMA A-Z Family Medical Encyclopedia;2004, p512 

    An encyclopedia entry for "monoamine oxidase inhibitors" is presented. It is one type of antidepressant drug which works by preventing the breakdown of certain neurotransmitters by the enzyme monoamine oxidase. common monoamine oxidase inhibitors include phenelzine and isocarboxazid. These drugs...

  • How drugs work.  // Current Health 2;Nov91, Vol. 18 Issue 3, p7 

    Explains how antidepressants work. Neurotransmitters; Tricyclics, such as Elavil and Tofranil; Monoamine oxidase inhibitors, such as Nardil and Parnate; Prozac.

  • Electroconvulsive therapy and monoamine oxidase inhibitors. Ribeiro, Rafael Bernardon; Rosa, Moacyr Alexandro; Rigonatti, Sérgio Paulo // Revista Brasileira de Psiquiatria;dez2008, Vol. 30 Issue 4, p406 

    A letter to the editor is presented about the potentiation of electroconvulsive therapy (ECT) with a monoamine oxidase inhibitor (MAOI) in treating refractory depression.

  • Delirium, thrombocytopenia, insomnia, and mild liver damage associated with MAOI withdrawal. Bellon, Alfredo; Coverdale, John H. // European Journal of Clinical Pharmacology;Dec2009, Vol. 65 Issue 12, p1269 

    A letter to the editor is presented on the impact of sudden withdrawal of monoamine oxidase inhibitors (MAOIs) drugs during treatment.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics